Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
Axel Åkerblom; Oskar Angerås; Li-Ming Gan; Lisette O. Jensen; Magnus Kjaer; Erik L. Grove; David Erlinge; Antti Saraste; Sara Svedlund; Maria Lagerström-Fermér; John Pernow; Eva Prescott; Marja Hedman
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
Axel Åkerblom
Oskar Angerås
Li-Ming Gan
Lisette O. Jensen
Magnus Kjaer
Erik L. Grove
David Erlinge
Antti Saraste
Sara Svedlund
Maria Lagerström-Fermér
John Pernow
Eva Prescott
Marja Hedman
Elsevier Inc.
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042826771
https://urn.fi/URN:NBN:fi-fe2021042826771
Tiivistelmä
levels is the primary efficacy outcome. FLAVOUR also aims to evaluate whether AZD5718 can improve coronary microvascular function, as measured by transthoracic colour Doppler-assisted coronary flow velocity reserve. Centrally pretrained study sonographers use standardized protocols and equipment. Additional outcomes include assessment of comprehensive echocardiographic parameters (including coronary flow, global strain, early diastolic strain rate and left ventricular ejection fraction), arterial stiffness, biomarkers, health-related quality of life, and safety. Specific anti-inflammatory therapies may represent novel promising treatments to reduce residual risk in patients with coronary artery disease. By combining primary pharmacodynamic and secondary cardiovascular surrogate efficacy outcomes, FLAVOUR aims to investigate the mechanistic basis and potential benefits of AZD5718 treatment in patients with coronary artery disease.
Kokoelmat
- Rinnakkaistallenteet [19206]